## AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

1-49. (Canceled)

50. (Currently Amended) A method for reducing restenosis following a vascular surgical procedure, the method comprising: locally administering to a human a biocompatible, non-biodegradable sustained release dosage form comprising a cytostatic amount of a free therapeutic agent dispersed in a polymer matrix, wherein said ~~free therapeutic agent~~ cytostatic amount of said free therapeutic agent inhibits a vascular smooth muscle cell activity without killing the cell ~~migration, does not exhibit substantial cytotoxicity, and does not substantially inhibit protein synthesis~~, and wherein said free therapeutic agent is not heparin, a radioisotope, a nitric oxide-releasing compound, suramin, methotrexate, adriamycin, a protein kinase inhibitor, staurosporin, an antisense oligonucleotide, a peptidic inhibitor, a growth factor inhibitor, a smooth muscle growth factor inhibitor, an endothelial growth factor inhibitor, a platelet inhibitor, integrin, triazolopyrimidine, or a prostaglandin.

51. (Cancelled)

52. (Previously presented) The method of claim 50, wherein the vascular surgical procedure comprises placement of a stent.

53. (Previously presented) The method of claim 50, wherein the vascular surgical procedure comprises angioplasty.

54. (Previously presented) The method of claim 50, wherein the locally administering comprises administering the free therapeutic agent directly to vascular smooth muscle tissue.

55. (Previously presented) The method of claim 50, wherein the release of the therapeutic agent from the dosage form occurs during or after the vascular procedure.

56. (New) The method of claim 50, wherein the free therapeutic agent comprises a cytostatic agent.

57. (New) The method of claim 50, wherein the free therapeutic agent comprises a cytoskeletal inhibitor.

58. (New) The method of claim 57, wherein the cytoskeletal inhibitor comprises taxol, or an analog or a derivative thereof.

59. (New) The method of claim 57, wherein the sustained release dosage form is a microparticulate.